Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDIT NASDAQ:GANX NASDAQ:HUMA NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.71-9.4%$2.94$1.66▼$4.54$292.74M2.163.02 million shs2.36 million shsGANXGain Therapeutics$1.70-8.6%$1.86$1.41▼$4.34$79.34M0.16644,344 shs615,211 shsHUMAHumacyte$1.35-9.4%$0.89$0.55▼$2.93$330.81M2.457.68 million shs6.42 million shsRCKTRocket Pharmaceuticals$2.75-5.8%$3.44$2.40▼$5.45$318.85M0.482.33 million shs2.55 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+7.55%-12.83%-1.64%+49.50%+64.29%GANXGain Therapeutics+4.20%-7.92%-0.53%-39.02%-6.53%HUMAHumacyte+6.05%+16.41%+65.21%+34.23%-43.35%RCKTRocket Pharmaceuticals0.00%-3.31%-17.51%-33.79%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.71-9.4%$2.94$1.66▼$4.54$292.74M2.163.02 million shs2.36 million shsGANXGain Therapeutics$1.70-8.6%$1.86$1.41▼$4.34$79.34M0.16644,344 shs615,211 shsHUMAHumacyte$1.35-9.4%$0.89$0.55▼$2.93$330.81M2.457.68 million shs6.42 million shsRCKTRocket Pharmaceuticals$2.75-5.8%$3.44$2.40▼$5.45$318.85M0.482.33 million shs2.55 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+7.55%-12.83%-1.64%+49.50%+64.29%GANXGain Therapeutics+4.20%-7.92%-0.53%-39.02%-6.53%HUMAHumacyte+6.05%+16.41%+65.21%+34.23%-43.35%RCKTRocket Pharmaceuticals0.00%-3.31%-17.51%-33.79%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.57Moderate Buy$5.4099.26% UpsideGANXGain Therapeutics 2.67Moderate Buy$8.50400.00% UpsideHUMAHumacyte 2.75Moderate Buy$6.43376.19% UpsideRCKTRocket Pharmaceuticals 2.38Hold$8.44207.07% UpsideCurrent Analyst Ratings BreakdownLatest GANX, RCKT, EDIT, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026HUMAHumacyte BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$2.005/27/2026EDITEditas Medicine TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026GANXGain Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/26/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.005/14/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.005/12/2026GANXGain Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026RCKTRocket Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/5/2026EDITEditas Medicine Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.50 ➝ $4.004/28/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$40.52M6.55N/AN/A$0.28 per share9.68GANXGain Therapeutics$50K1,450.10N/AN/A$0.48 per share3.54HUMAHumacyte$2.04M146.93N/AN/A$0.02 per share67.50RCKTRocket PharmaceuticalsN/AN/AN/AN/A$2.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%8/11/2026 (Estimated)GANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)HUMAHumacyte-$40.83M-$0.57N/AN/AN/A-4,836.06%-2,914.18%-89.45%8/10/2026 (Estimated)RCKTRocket Pharmaceuticals-$223.12M-$1.87N/AN/AN/AN/A-69.61%-58.63%8/6/2026 (Estimated)Latest GANX, RCKT, EDIT, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026HUMAHumacyte-$0.10-$0.09+$0.01-$0.09$1.46 million$0.50 million5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A5/7/2026Q1 2026RCKTRocket Pharmaceuticals-$0.41-$0.42-$0.01-$0.42$4.47 millionN/A5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million3/27/2026Q4 2025HUMAHumacyte-$0.13-$0.13N/A-$0.13$1.35 million$0.47 million3/26/2026Q4 2025GANXGain Therapeutics-$0.14-$0.11+$0.03-$0.11$0.03 millionN/A3/9/2026Q4 2025EDITEditas Medicine-$0.27-$0.06+$0.21-$0.06$8.77 million$24.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.223.22GANXGain Therapeutics0.024.694.69HUMAHumacyte5.463.933.32RCKTRocket Pharmaceuticals0.086.126.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%GANXGain Therapeutics11.97%HUMAHumacyte44.71%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine3.10%GANXGain Therapeutics4.15%HUMAHumacyte3.10%RCKTRocket Pharmaceuticals21.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23097.91 million94.87 millionOptionableGANXGain Therapeutics2042.65 million40.88 millionOptionableHUMAHumacyte150222.02 million215.14 millionOptionableRCKTRocket Pharmaceuticals240109.19 million85.94 millionOptionableGANX, RCKT, EDIT, and HUMA HeadlinesRecent News About These CompaniesRocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 5 at 5:01 PM | seekingalpha.comRocket Pharmaceuticals (NASDAQ:RCKT) Stock Crosses Below 200-Day Moving Average - Should You Sell?June 3 at 2:43 AM | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) CEO Gaurav Shah Sells 55,684 SharesMay 27, 2026 | insidertrades.comRocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?May 20, 2026 | finance.yahoo.comRocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6MMay 18, 2026 | finance.yahoo.comInsider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells 3,361 Shares of StockMay 15, 2026 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by AnalystsMay 13, 2026 | marketbeat.comLifesci Capital Analysts Raise Earnings Estimates for RCKTMay 12, 2026 | marketbeat.comSarbani Chaudhuri Sells 17,650 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) StockMay 12, 2026 | insidertrades.comRCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in FocusMay 11, 2026 | zacks.comRocket Pharmaceuticals (NASDAQ:RCKT) Receives "Buy" Rating from Chardan CapitalMay 11, 2026 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings ResultsMay 9, 2026 | marketbeat.comRocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI)April 29, 2026 | theglobeandmail.comRocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherApril 28, 2026 | joplinglobe.comJAnalysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)April 16, 2026 | theglobeandmail.comRCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseMarch 30, 2026 | zacks.comWhy Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADIMarch 29, 2026 | insidermonkey.comRocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 TranscriptMarch 27, 2026 | seekingalpha.comRocket Pharmaceuticals secures FDA approval for gene therapy KRESLADIMarch 27, 2026 | proactiveinvestors.caPRocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)March 27, 2026 | joplinglobe.comJNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026These 3 CLO ETFs Target a Niche Corner of the Fixed-Income MarketBy Nathan Reiff | May 31, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026Viking Sails to All-Time Highs—Fundamentals Signal More to ComeBy Chris Markoch | May 15, 2026AI Demand Fuels Strong Q1 Earnings for Constellation EnergyBy Chris Markoch | May 12, 2026GANX, RCKT, EDIT, and HUMA Company DescriptionsEditas Medicine NASDAQ:EDIT$2.71 -0.28 (-9.36%) Closing price 04:00 PM EasternExtended Trading$2.76 +0.05 (+1.99%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Gain Therapeutics NASDAQ:GANX$1.70 -0.16 (-8.60%) Closing price 04:00 PM EasternExtended Trading$1.74 +0.04 (+2.59%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Humacyte NASDAQ:HUMA$1.35 -0.14 (-9.40%) Closing price 04:00 PM EasternExtended Trading$1.38 +0.02 (+1.85%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Rocket Pharmaceuticals NASDAQ:RCKT$2.75 -0.17 (-5.82%) Closing price 04:00 PM EasternExtended Trading$2.78 +0.03 (+1.24%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
